Intra-Cellular Therapies (ITCI) Tops Q2 EPS by 8c
Tweet
Share
E-mailGet Alerts ITCI Hot Sheet
Join SI Premium – FREE
Intra-Cellular Therapies (NASDAQ: ITCI) reported Q2 EPS of ($0.71), $0.08 better than the analyst estimate of ($0.79). Revenue for the quarter came in at $223.45 thousand versus the consensus estimate of $20 thousand.
For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KB Home (KBH) Tops Q3 EPS by 16c
- MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
- Activist Corvex seeks Whitbread board seat over strategy concerns
Create E-mail Alert Related Categories
EarningsRelated Entities
The Children's Investment Fund (TCI), EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
